Jump to: navigation, search
Systematic (IUPAC) name
acetic acid
CAS number 51-24-1
ATC code H03AA04 D11AX08
PubChem 5803
Chemical data
Formula C14H9I3O4 
Mol. mass 621.932 g/mol
Synonyms 3,3',5-triiodothyroacetic acid
Pharmacokinetic data
Bioavailability  ?
Protein binding Presumed high
Metabolism Hepatic glucuronidation
Half life  ?
Excretion Biliary
Therapeutic considerations
Pregnancy cat.


Legal status
Routes  ?

WikiDoc Resources for



Most recent articles on Tiratricol

Most cited articles on Tiratricol

Review articles on Tiratricol

Articles on Tiratricol in N Eng J Med, Lancet, BMJ


Powerpoint slides on Tiratricol

Images of Tiratricol

Photos of Tiratricol

Podcasts & MP3s on Tiratricol

Videos on Tiratricol

Evidence Based Medicine

Cochrane Collaboration on Tiratricol

Bandolier on Tiratricol

TRIP on Tiratricol

Clinical Trials

Ongoing Trials on Tiratricol at Clinical Trials.gov

Trial results on Tiratricol

Clinical Trials on Tiratricol at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Tiratricol

NICE Guidance on Tiratricol


FDA on Tiratricol

CDC on Tiratricol


Books on Tiratricol


Tiratricol in the news

Be alerted to news on Tiratricol

News trends on Tiratricol


Blogs on Tiratricol


Definitions of Tiratricol

Patient Resources / Community

Patient resources on Tiratricol

Discussion groups on Tiratricol

Patient Handouts on Tiratricol

Directions to Hospitals Treating Tiratricol

Risk calculators and risk factors for Tiratricol

Healthcare Provider Resources

Symptoms of Tiratricol

Causes & Risk Factors for Tiratricol

Diagnostic studies for Tiratricol

Treatment of Tiratricol

Continuing Medical Education (CME)

CME Programs on Tiratricol


Tiratricol en Espanol

Tiratricol en Francais


Tiratricol in the Marketplace

Patents on Tiratricol

Experimental / Informatics

List of terms related to Tiratricol


Tiratricol (also known as TRIAC) is a thyroid hormone analogue. It is indicated in the management of thyroid hormone resistance syndrome[1] and is used, in combination with levothyroxine, to suppress thyroid-stimulating hormone production in patients with thyroid cancer.

Tiratricol has also been widely marketed, under various trade names, as a weight loss aid. In 1999 and 2000, the United States Food and Drug Administration and Health Canada both issued warnings to the public regarding the use of dietary supplements containing tiratricol.[2][3]

Legal status

Tiratricol is not approved for sale in Canada or the United States. It was once an approved drug in Brazil, but its marketing authorization was suspended in 2003, effectively prohibiting its sale.[4]


  1. Carvalho GA, Ramos HE (2004). "[Thyroid hormone resistance syndrome]" (in Portuguese). Arq Bras Endocrinol Metabol 48 (1): 83–92. doi:/S0004-27302004000100010. PMID 15611821. Free full textPDF (95.3 KiB)
  2. U.S. Food and Drug Administration (November 21 2000). FDA Warns Against Consuming Dietary Supplements Containing Tiratricol. Press release.
  3. Health Canada (December 2 1999). Health Canada issues warning on products containing Tiratricol (TRIAC). Press release.
  4. Anvisa suspende Tiratricol (Portuguese). Brazilian Society of Endocrinology and Metabolism.